Gene: ARID3A

1820
BRIGHT|DRIL1|DRIL3|E2FBP1
AT-rich interaction domain 3A
protein-coding
19p13.3
Ensembl:ENSG00000116017 MIM:603265 Vega:OTTHUMG00000182018 UniprotKB:Q99856
NC_000019.10
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.349e-1 (AD)  4.992e-2 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs1637995chr19:960445 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg22035959chr19:951681ARID3A1.600e-9Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
COLGALT10.774
DOK30.751
GMIP0.739
STXBP20.738
KCNK60.723
DOT1L0.721
PIM10.721
MTMR110.719
OSCAR0.712
MKNK10.712

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
DIAPH3-0.352
HES5-0.348
OR4F5-0.311
RXRG-0.309
HPDL-0.299
REN-0.299
ROPN1B-0.293
GLIPR1L2-0.291
OR4F29-0.289
ARSF-0.277

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0299552-nitrotoluene2-nitrotoluene results in increased expression of ARID3A mRNA15612046
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID3A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID3A mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of ARID3A mRNA22230336
D000082AcetaminophenAcetaminophen affects the expression of ARID3A mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of ARID3A mRNA22100608
D001280AtrazineAtrazine results in increased expression of ARID3A mRNA22378314
C044887beta-methylcholinebeta-methylcholine affects the expression of ARID3A mRNA21179406
C006780bisphenol Abisphenol A affects the methylation of ARID3A promoter27334623
C006780bisphenol Abisphenol A results in decreased expression of ARID3A mRNA25181051
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide affects the expression of ARID3A mRNA23410634
D019256Cadmium ChlorideCadmium Chloride results in increased methylation of ARID3A promoter22457795
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of ARID3A20938992
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ARID3A gene20938992
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ARID3A mRNA20938992
D003300CopperCopper deficiency results in increased expression of ARID3A mRNA26033743
D019327Copper SulfateCopper Sulfate results in decreased expression of ARID3A mRNA19549813
D003471CuprizoneCuprizone results in decreased expression of ARID3A mRNA26577399
C010902decabromobiphenyl etherdecabromobiphenyl ether results in increased expression of ARID3A mRNA23914054
D015946Ethylene DibromideEthylene Dibromide results in increased expression of ARID3A mRNA15612046
C000944dicrotophosdicrotophos results in increased expression of ARID3A mRNA28302478
D019422Dietary SucroseDietary Sucrose results in increased expression of ARID3A mRNA26033743
D004642EmodinEmodin results in increased expression of ARID3A mRNA15612046
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of ARID3A20938992
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ARID3A gene20938992
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ARID3A mRNA20938992
C004312glycidolglycidol results in increased expression of ARID3A mRNA15612046
C029424hydrazinehydrazine results in decreased expression of ARID3A mRNA15282401
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of ARID3A mRNA23410634
D058185Magnetite NanoparticlesMagnetite Nanoparticles results in increased expression of ARID3A mRNA24525745
D008713MethimazoleMethimazole results in increased expression of ARID3A mRNA22504374
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of ARID3A20938992
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ARID3A gene20938992
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ARID3A mRNA20938992
C036868methyl carbamatemethyl carbamate results in increased expression of ARID3A mRNA15612046
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of ARID3A mRNA23179753
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of ARID3A mRNA"25554681|2562005
C028007nickel monoxidenickel monoxide results in increased expression of ARID3A mRNA19167457
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID3A mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of ARID3A mRNA26272509
D011441PropylthiouracilPropylthiouracil results in increased expression of ARID3A mRNA22504374
D015125OxyquinolineOxyquinoline results in increased expression of ARID3A mRNA15612046
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of ARID3A mRNA28922406
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of ARID3A mRNA24058054
C009495titanium dioxidetitanium dioxide results in increased expression of ARID3A mRNA27760801
D014635Valproic AcidValproic Acid results in decreased expression of ARID3A mRNA29154799
D014635Valproic AcidValproic Acid results in increased expression of ARID3A mRNA23179753
D014635Valproic AcidValproic Acid results in increased methylation of ARID3A gene29154799
D024483Vitamin K 3Vitamin K 3 affects the expression of ARID3A mRNA20044591|2341063
D015032ZincZinc deficiency results in increased expression of ARID3A mRNA22171008

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000977RNA polymerase II regulatory region sequence-specific DNA binding-IBA21873635  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0001228transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding-IBA21873635  
GO:0003682chromatin binding-IEA-  
GO:0005515protein binding-IPI19214191  25416956  
GO:0042803protein homodimerization activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006366transcription by RNA polymerase II-IEA-  
GO:0006977DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest-TAS-  
GO:0045944positive regulation of transcription by RNA polymerase II-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005654nucleoplasm-IDA-  
GO:0005654nucleoplasm-TAS-  
GO:0005829cytosol-IDA-  
GO:0043231intracellular membrane-bounded organelle-IDA-  
GO:0045121membrane raft-IDA21955986  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-212436Generic Transcription PathwayTAS
R-HSA-3700989Transcriptional Regulation by TP53TAS
R-HSA-6791312TP53 Regulates Transcription of Cell Cycle GenesTAS
R-HSA-6804116TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle ArrestTAS
R-HSA-73857RNA Polymerase II TranscriptionTAS
R-HSA-74160Gene expression (Transcription)TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal